CoChat

3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained

Open access

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

The potential of a spheroid tumor model composed of cells in different proliferative and metabolic states for the development of new anticancer strategies has been amply demonstrated. However, there is little or no information in the literature on the problems of reproducibility of data originating from experiments using 3D models. Our analyses, carried out using a novel open source software capable of performing an automatic image analysis of 3D tumor colonies, showed that a number of morphology parameters affect the response of large spheroids to treatment. In particular, we found that both spheroid volume and shape may be a source of variability. We also compared some commercially available viability assays specifically designed for 3D models. In conclusion, our data indicate the need for a pre-selection of tumor spheroids of homogeneous volume and shape to reduce data variability to a minimum before use in a cytotoxicity test. In addition, we identified and validated a cytotoxicity test capable of providing meaningful data on the damage induced in large tumor spheroids of up to diameter in 650 μm by different kinds of treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep19103

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic flow-chart of the image-based approach proposed to select a homogeneous population of large spheroids. (a) Spheroids of variable dimension and shape affect data reproducibility when they are used as an in vitro model to test drugs and radiotherapy treatments. (b) To select a sub-population of homogeneous spheroids, spheroids are seeded in low-attachment 96-well plates (one spheroid/well) and a brightfield image is acquired using an inverted widefield microscope (c). (d) AnaSP software (http://sourceforge.net/p/anasp/) can be used to automatically compute (e) several morphological parameters (3D reconstructions obtained by using ReViSP, http://sourceforge.net/p/revisp/). (f) A sub-population of homogeneous spheroids can be selected by analyzing volume and sphericity. The plate wells containing spheroids with similar volume and sphericity are shown in green.
Figure 1 Schematic flow-chart of the image-based approach proposed to select a homogeneous population of large spheroids. (a) Spheroids of variable dimension and shape affect data reproducibility when they are used as an in vitro model to test drugs and radiotherapy treatments. (b) To select a sub-population of homogeneous spheroids, spheroids are seeded in low-attachment 96-well plates (one spheroid/well) and a brightfield image is acquired using an inverted widefield microscope (c). (d) AnaSP software (http://sourceforge.net/p/anasp/) can be used to automatically compute (e) several morphological parameters (3D reconstructions obtained by using ReViSP, http://sourceforge.net/p/revisp/). (f) A sub-population of homogeneous spheroids can be selected by analyzing volume and sphericity. The plate wells containing spheroids with similar volume and sphericity are shown in green.CC BY · PubMed Central
Figure 2 Spheroid-shape heterogeneity and evolution over time. (a) Very few spheroids generated by the RCCS method initially have a spherical shape (brightfield images of A549 3D cultures obtained using an Olympus inverted microscope with attached Nikon high speed DS-Vi1 colour digital camera, scale bar = 1 mm). After approximately one week of culture (spheroidization time), the majority can be considered as a real “spherical” spheroid (SI ≥ 0.90). (b) After the spheroidization period, a number of morphological classes of spheroids can still be observed: spherical, ellipsoidal, Figure 8-shaped and irregular. (c) We observed that the spherical-shaped spheroids generally maintain their morphology over time. Conversely, spheroids with a non-spherical shape after spheroidization are characterized by substantial morphological changes (i.e. cell detachment, budding of secondary spheroids).
Figure 2 Spheroid-shape heterogeneity and evolution over time. (a) Very few spheroids generated by the RCCS method initially have a spherical shape (brightfield images of A549 3D cultures obtained using an Olympus inverted microscope with attached Nikon high speed DS-Vi1 colour digital camera, scale bar = 1 mm). After approximately one week of culture (spheroidization time), the majority can be considered as a real “spherical” spheroid (SI ≥ 0.90). (b) After the spheroidization period, a number of morphological classes of spheroids can still be observed: spherical, ellipsoidal, Figure 8-shaped and irregular. (c) We observed that the spherical-shaped spheroids generally maintain their morphology over time. Conversely, spheroids with a non-spherical shape after spheroidization are characterized by substantial morphological changes (i.e. cell detachment, budding of secondary spheroids).CC BY · PubMed Central
Figure 3 Relation between shape and viability of cells composing the spheroids. (a) Brightfield image of A549 spherical colony (top figure) and the same image with pathophysiological gradients schematically reported (bottom figure). Scale bar = 0.1mm. (b) Optical section of a live, spherical tumor spheroid obtained with light sheet fluorescence microscopy (LSFM, Lightsheet Z.1, Zeiss). Green = calcein-positive (live) cells; red = ethidium-positive (dead) cells. Scale bar = 0.2 mm. The fluorescence intensity profiles for both channels show the different distribution of live and dead cells in the spheroid structure; plots normalized on respective maximum value. (c) Variations in tumor shape are also accompanied by changes in the dimension of the inner core and in the thickness of the external layers mainly composed of actively proliferating cells. Brightfield images; scale bar = 0.1 mm. (d) Cell viability of tumor spheroids with homogeneous volume but different shapes (spherical vs. non-spherical) measured by CellTiter-Glo®3D Cell Viability assay. Bars = standard deviation (SD); means were calculated from a group of 15 spheroids/data set (n). *P = 0.045.
Figure 3 Relation between shape and viability of cells composing the spheroids. (a) Brightfield image of A549 spherical colony (top figure) and the same image with pathophysiological gradients schematically reported (bottom figure). Scale bar = 0.1mm. (b) Optical section of a live, spherical tumor spheroid obtained with light sheet fluorescence microscopy (LSFM, Lightsheet Z.1, Zeiss). Green = calcein-positive (live) cells; red = ethidium-positive (dead) cells. Scale bar = 0.2 mm. The fluorescence intensity profiles for both channels show the different distribution of live and dead cells in the spheroid structure; plots normalized on respective maximum value. (c) Variations in tumor shape are also accompanied by changes in the dimension of the inner core and in the thickness of the external layers mainly composed of actively proliferating cells. Brightfield images; scale bar = 0.1 mm. (d) Cell viability of tumor spheroids with homogeneous volume but different shapes (spherical vs. non-spherical) measured by CellTiter-Glo®3D Cell Viability assay. Bars = standard deviation (SD); means were calculated from a group of 15 spheroids/data set (n). *P = 0.045.CC BY · PubMed Central
Figure 4 Evaluation of cell viability assay in tumor spheroid models. (a) Homogeneous-sized and -shaped A549 spheroids were treated for 72 h with three concentrations (10, 33 and 100 μM) of 4-HPR-HSA and viability was evaluated using 3 different assays: Trypan blue exclusion test, data are the mean of four repetitions, n = 4 (I), Perfecta3D-Cell Viability Assay, n = 3 (II), and CellTiter-Glo®3D Cell Viability assay, n = 3 (III). Brightfield imaging of untreated spheroids (control, CTR) and spheroids treated with increasing doses of 4-HPR-HSA (left to right) was acquired after a 72-h treatment; Scale bar= 0.25 mm. The corresponding 3D reconstructions were obtained by using ReViSP, http://sourceforge.net/p/revisp/. (b) Homogeneous-sized and -shaped A549 spheroids were exposed to four different radiation schedules (2 Gy × 5, 5 Gy × 5, 6.5 Gy × 5 and 7.5 Gy × 5 days). Cell viability was evaluated 4 and 25 days after the end of radiation treatment. Brightfield images of spheroids treated with 7.5Gy × 5 days were taken 4 and 25 days after the end of radiation treatment. Scale bar = 0.25 mm.
Figure 4 Evaluation of cell viability assay in tumor spheroid models. (a) Homogeneous-sized and -shaped A549 spheroids were treated for 72 h with three concentrations (10, 33 and 100 μM) of 4-HPR-HSA and viability was evaluated using 3 different assays: Trypan blue exclusion test, data are the mean of four repetitions, n = 4 (I), Perfecta3D-Cell Viability Assay, n = 3 (II), and CellTiter-Glo®3D Cell Viability assay, n = 3 (III). Brightfield imaging of untreated spheroids (control, CTR) and spheroids treated with increasing doses of 4-HPR-HSA (left to right) was acquired after a 72-h treatment; Scale bar= 0.25 mm. The corresponding 3D reconstructions were obtained by using ReViSP, http://sourceforge.net/p/revisp/. (b) Homogeneous-sized and -shaped A549 spheroids were exposed to four different radiation schedules (2 Gy × 5, 5 Gy × 5, 6.5 Gy × 5 and 7.5 Gy × 5 days). Cell viability was evaluated 4 and 25 days after the end of radiation treatment. Brightfield images of spheroids treated with 7.5Gy × 5 days were taken 4 and 25 days after the end of radiation treatment. Scale bar = 0.25 mm.CC BY · PubMed Central
Figure 5 Validation of data obtained with CellTiter-Glo®3D Cell Viability assay in fibroblastic spheroids. (a) Spheroids were generated using the pellet culture system. The spheroids obtained were then subdivided into 5 volumetric categories: 0.025, 0.050, 0.100, 0.150, and 0.300 mm3, corresponding to an equivalent diameter of approximately 350, 450, 600, 650, and 850 μm. Using 9 homogeneous-shaped spheroids for each category, we performed the CellTiter-Glo®3D Cell Viability assay to investigate the relation between bioluminescence and volume. Bioluminescence increased in a linear manner up to a diameter of 650 μM (continuous red line). A significant deviance from linearity (green line) was observed for spheroids with a diameter of 850 μM. (b) Homogeneous-sized and -shaped MRC-5 spheroids were stained with Hoechst 33342 alone (left spheroids) or mixed with the CellTiter-Glo®3D reagent solution (right spheroids), as described in the Results section. Optical sections passing through the centre of the 3D structures and the corresponding maximum projections were captured with LSFM after 30 minutes. The fluorescence intensity profiles for the blue channel show a different degree of Hoechst 33342 penetration in the spheroid structures. Scale bar = 0.1 mm. (c) LSFM optical sections and fluorescence intensity profiles of spherical MRC-5 spheroids of increasing volume (left to right). The images show the complete penetration of Hoechst 33342 and CellTiter-Glo®3D reagent mixture in spheroids of up to 650 μm in diameter; Scale bar = 0.25 mm.
Figure 5 Validation of data obtained with CellTiter-Glo®3D Cell Viability assay in fibroblastic spheroids. (a) Spheroids were generated using the pellet culture system. The spheroids obtained were then subdivided into 5 volumetric categories: 0.025, 0.050, 0.100, 0.150, and 0.300 mm3, corresponding to an equivalent diameter of approximately 350, 450, 600, 650, and 850 μm. Using 9 homogeneous-shaped spheroids for each category, we performed the CellTiter-Glo®3D Cell Viability assay to investigate the relation between bioluminescence and volume. Bioluminescence increased in a linear manner up to a diameter of 650 μM (continuous red line). A significant deviance from linearity (green line) was observed for spheroids with a diameter of 850 μM. (b) Homogeneous-sized and -shaped MRC-5 spheroids were stained with Hoechst 33342 alone (left spheroids) or mixed with the CellTiter-Glo®3D reagent solution (right spheroids), as described in the Results section. Optical sections passing through the centre of the 3D structures and the corresponding maximum projections were captured with LSFM after 30 minutes. The fluorescence intensity profiles for the blue channel show a different degree of Hoechst 33342 penetration in the spheroid structures. Scale bar = 0.1 mm. (c) LSFM optical sections and fluorescence intensity profiles of spherical MRC-5 spheroids of increasing volume (left to right). The images show the complete penetration of Hoechst 33342 and CellTiter-Glo®3D reagent mixture in spheroids of up to 650 μm in diameter; Scale bar = 0.25 mm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Items 801–900 of 1,000

Metadata

Authors
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A.
Affiliations
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • University of Bologna (IT)
  • Istituto Ortopedico Rizzoli (IT)
Corresponding author
Tesei, Anna
Venue
Scientific Reports
Published
2016-01-11
Volume
6
Issue
1
Pages
19103-19103
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2236643502
Cited by
1,144
References
43
Citations by year
2026: 97 · 2025: 127 · 2024: 124 · 2023: 105 · 2022: 112 · 2021: 117 · 2020: 138 · 2019: 118 · 2018: 118 · 2017: 70 · 2016: 17
FWCI
57.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
Funders
  • Ministero della Salute
  • Istituto Ortopedico Rizzoli di Bologna
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
Keywords
tumor spheroids, spheroid morphology, automated image analysis, viability assay, cytotoxicity assay
MeSH terms
Cell Survival, Drug Screening Assays, Antitumor, Fibroblasts, Humans, Models, Biological, Tumor Cells, Cultured, Reproducibility of Results, Spheroids, Cellular, Imaging, Three-Dimensional, Cell Shape

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.